These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8425810)
1. Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis. Frankenburg S; Gross A; Jonas F; Klaus S Int J Dermatol; 1993 Jan; 32(1):68-70. PubMed ID: 8425810 [TBL] [Abstract][Full Text] [Related]
2. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions. Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Ravis WR; Llanos-Cuentas A; Sosa N; Kreishman-Deitrick M; Kopydlowski KM; Nielsen C; Smith KS; Smith PL; Ransom JH; Lin YJ; Grogl M Antimicrob Agents Chemother; 2013 Oct; 57(10):4809-15. PubMed ID: 23877689 [TBL] [Abstract][Full Text] [Related]
4. Occlusive paromomycin for cutaneous leishmaniasis. Bell SA; Schaller M; Röcken M Lancet; 1997 Jan; 349(9044):29. PubMed ID: 8988124 [No Abstract] [Full Text] [Related]
5. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. Grogl M; Schuster BG; Ellis WY; Berman JD J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319 [TBL] [Abstract][Full Text] [Related]
6. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Asilian A; Davami M Clin Exp Dermatol; 2006 Sep; 31(5):634-7. PubMed ID: 16780497 [TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole. Chacko A; Joseph M; Feltis T; Morris SK Am J Trop Med Hyg; 2016 Oct; 95(4):793-794. PubMed ID: 27549634 [TBL] [Abstract][Full Text] [Related]
8. Development of in vitro parameters of cell-mediated immunity in the course of human cutaneous leishmaniasis infection. Frankenburg S; Jonas F; Gross A; Klaus S Am J Trop Med Hyg; 1993 Apr; 48(4):512-8. PubMed ID: 8480859 [TBL] [Abstract][Full Text] [Related]
9. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819 [TBL] [Abstract][Full Text] [Related]
10. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B; Abbaszadeh B; Khamesipour A Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817 [TBL] [Abstract][Full Text] [Related]
11. Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin. Veraldi S; Benzecry Mancin V; Faraci AG; Nazzaro G Int J Dermatol; 2020 Jul; 59(7):e251-e252. PubMed ID: 31975375 [No Abstract] [Full Text] [Related]
12. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Soto J; Fuya P; Herrera R; Berman J Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of paromomycin sulphate topical ointment as effective therapeutic agent in cutaneous leishmaniasis. Sahibzada NJ; Tareen AK; Khursheed T; Darr N J Pak Med Assoc; 1996 Mar; 46(3):53-5. PubMed ID: 8991348 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of paromomicin and gentamicin patches in the treatment of cutaneous leishmaniasis. Asilian A; Faghihi G; Siadat AH; Hejazi H; Shahtalebi M; Sadeghian G; Mostaghim M; Radan MR East Mediterr Health J; 2006 Nov; 12(6):931-3. PubMed ID: 17333845 [No Abstract] [Full Text] [Related]
15. Ablative fractional laser resurfacing with topical paromomycin as adjunctive treatment for a recalcitrant cutaneous leishmaniasis wound. Basnett A; Nguyen TA; Cannavino C; Krakowski AC Lasers Surg Med; 2015 Dec; 47(10):788-91. PubMed ID: 26419328 [TBL] [Abstract][Full Text] [Related]
16. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study. Krause G; Kroeger A Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776 [No Abstract] [Full Text] [Related]
17. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. el-On J; Halevy S; Grunwald MH; Weinrauch L J Am Acad Dermatol; 1992 Aug; 27(2 Pt 1):227-31. PubMed ID: 1430361 [TBL] [Abstract][Full Text] [Related]
18. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. Ben Salah A; Ben Messaoud N; Guedri E; Zaatour A; Ben Alaya N; Bettaieb J; Gharbi A; Belhadj Hamida N; Boukthir A; Chlif S; Abdelhamid K; El Ahmadi Z; Louzir H; Mokni M; Morizot G; Buffet P; Smith PL; Kopydlowski KM; Kreishman-Deitrick M; Smith KS; Nielsen CJ; Ullman DR; Norwood JA; Thorne GD; McCarthy WF; Adams RC; Rice RM; Tang D; Berman J; Ransom J; Magill AJ; Grogl M N Engl J Med; 2013 Feb; 368(6):524-32. PubMed ID: 23388004 [TBL] [Abstract][Full Text] [Related]
19. Occlusive paromomycin for cutaneous leishmaniasis. Bryceson AD Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342 [No Abstract] [Full Text] [Related]
20. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Moosavi Z; Nakhli A; Rassaii S Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282 [No Abstract] [Full Text] [Related] [Next] [New Search]